European Journal of Clinical Pharmacology

, Volume 20, Issue 2, pp 85–89 | Cite as

Prolonged Q-T interval and severe tachyarrhythmias, common features of sotalol intoxication

  • P. J. Neuvonen
  • E. Elonen
  • T. Vuorenmaa
  • M. Laakso


The findings in six patients admitted to hospital 0.5–4.5 h after the ingestion of an overdose of 2.4–8 g sotalol are described. In addition to bradycardia and hypotension, all patients had a considerably prolonged corrected Q-T interval, up to 172±8% of normal. Severe ventricular tachyarrhythmias occurred in five of the six patients, the risk was greatest up to 20 h after the ingestion of sotalol. The long Q-T interval returned to normal over 3 to 4 days, which is consistent with the long half-life of sotalol. In addition to its beta-blocking action, sotalol has marked electrophysiological properties of a Class III antiarrhythmic drugs, which are likely to be able to account for its observed effects. Special attention should be paid to the risk of severe ventricular arrhythmias in sotalol intoxications.

Key words

beta-blockers sotalol intoxication Q-T interval tachyarrhythmias 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Editorial (1978) Self-poisoning with beta-blockers. Br Med J 2: 1010–1011Google Scholar
  2. 2.
    Editorial (1980) Beta-blocker poisoning. Lancet 1: 803–804Google Scholar
  3. 3.
    Kristinsson J, Johannesson T (1977) A case of fatal propranolol intoxication. Acta Pharmacol Toxicol 41: 190–192Google Scholar
  4. 4.
    Khan A, Muscat-Brown JM (1977) Fatal oxprenolol poisoning. Br Med J 1: 552Google Scholar
  5. 5.
    Montagna M, Groppi A (1980) Fatal sotalol poisoning. Arch Toxicol 43: 221–226Google Scholar
  6. 6.
    Vaughan Williams EM (1970) Classification of antiarrhythmic drugs. In: Sandoe E, Flensted-Jensen E, Olsen, KH (eds) Symposium on cardiac arrhythmias. Astra Publishers, pp 449–472Google Scholar
  7. 7.
    Singh BN, Vaughan Williams EM (1970) A third class of antiarrhythmic action. Effects on atrial and ventricular intracellular potentials and other pharmacological actions on cardiac muscle of MJ 1999 and AH 3474. Br J Pharmacol 39: 675–687Google Scholar
  8. 8.
    Strauss HC, Bigger JT Jr, Hoffman BF (1970) Electrophysiological and beta-receptor blocking effects of MJ 1999 on dog and rabbit cardiac tissue. Circ Res 21: 661–678Google Scholar
  9. 9.
    Elonen E, Neuvonen PJ, Tarssanen L, Kala R (1979) Sotalol intoxication with prolonged Q-T interval and severe tachyarrhythmias. Br Med J 1: 1184Google Scholar
  10. 10.
    Neuvonen PJ, Elonen E, Tarssanen L (1979) Sotalol intoxication, two patients with concentration-effect relationships. Acta Pharmacol Toxicol 45: 52–57Google Scholar
  11. 11.
    Sundquist H, Anttila M, Arstila M (1974) Antihypertensive effects of practolol and sotalol. Clin Pharmacol Ther 16: 465–472Google Scholar
  12. 12.
    Wit AL, Hoffman BF, Rosen MR (1975) Electrophysiology and pharmacology of cardiac arrhythmias IX. Cardiac electrophysiologic effects of beta adrenergic receptor stimulation and blockade. Part C. Am Heart J 90: 795–803Google Scholar
  13. 13.
    Theisen K, Jahrmärker H (1975) Re-entry-Mechanismus ventrikulärer Tachykardien bei inhomogener Repolarisation. Dtsch Med Wochenschr 100: 1141–1147Google Scholar
  14. 14.
    Deglin SM, Deglin JM, Chung EK (1977) Drug-induced cardiovascular diseases. Drugs 14: 29–40Google Scholar
  15. 15.
    McComb JM, Logan KR, Khan MM, Geddes JS, Adgey AAJ (1980) Amiodarone-induced ventricular fibrillation. Eur J Cardiol 11: 381–385Google Scholar
  16. 16.
    Parmley WW (1974) Inotropic and antiarrhythmic effects of sotalol. In: Snart AG (ed) Adv in beta-adrenergic blocking therapy, Vol 3: Sotalol. Proc of Int Symp, Rome, Italy May 1974. Excerpta Medica, Amsterdam, pp 11–19Google Scholar
  17. 17.
    Frankl WS, Soloff LA (1968) Sotalol: a new, safe beta adrenergic receptor blocking agent. Am J Cardiol 22: 266–272Google Scholar
  18. 18.
    Verniory A, Staroukine M, Telerman M, Delwiche F (1974) Effect of sotalol on arterial blood pressure and renin-angiotensin system in hypertensive patients. In: Snart AG (ed) Adv. in beta-adrenergic blocking therapy, Vol 3: Sotalol. Proc of Int Symp, Rome, Italy, May 1974, Excerpta Medica, Amsterdam, pp 36–49Google Scholar
  19. 19.
    Sundquist HK, Anttila M, Forsström J, Kasanen A (1975) Serum levels and half-life of sotalol in chronic renal failure. Ann Clin Res 7: 442–446Google Scholar
  20. 20.
    Anttila M, Arstila M, Pfeffer M, Tikkanen R, Vallinkoski V, Sundquist H (1976) Human pharmacokinetics of sotalol. Acta Pharmacol Toxicol 39: 118–128Google Scholar
  21. 21.
    Brown HC, Carruthers SG, Kelly JG, McDevitt DG, Shanks RG (1976) Observations on the efficacy and pharmacokinetics of sotalol after oral administration. Eur J Clin Pharmacol 9: 367–372Google Scholar

Copyright information

© Springer-Verlag 1981

Authors and Affiliations

  • P. J. Neuvonen
    • 1
  • E. Elonen
    • 2
  • T. Vuorenmaa
    • 3
  • M. Laakso
    • 4
  1. 1.Department of Clinical PharmacologyUniversity of HelsinkiFinland
  2. 2.Third Department of MedicineUniversity of HelsinkiFinland
  3. 3.Department of MedicineUniversity of TurkuFinland
  4. 4.Department of MedicineUniversity of KuopioFinland

Personalised recommendations